ALX Oncology (NASDAQ:ALXO) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
by Danessa Lincoln · The Markets DailyALX Oncology (NASDAQ:ALXO – Get Free Report) issued its earnings results on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports.
ALX Oncology Stock Performance
Shares of ALXO opened at $1.04 on Monday. ALX Oncology has a 1 year low of $0.86 and a 1 year high of $2.66. The company has a market cap of $143.81 million, a price-to-earnings ratio of -0.92 and a beta of 0.61. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. The firm has a fifty day moving average of $1.35 and a 200-day moving average of $1.81.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on ALXO shares. Weiss Ratings upgraded ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen cut shares of ALX Oncology from a “hold” rating to a “sell” rating in a report on Saturday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.75.
View Our Latest Analysis on ALX Oncology
ALX Oncology Company Profile
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.
Featured Stories
- Five stocks we like better than ALX Oncology
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal